Home
Statistics
Acknowledgment
Enquire
Keyword Search
Complex Search
Segment Search
Peptide Mapping
Browse On
Mode of delivery
Animal model
Origin/Source
Peptide Length
Similarity
BLAST Search
Smith-Waterman
General
Help or Guide
Data Submission
Curators
Developers
Contact Us
Browse result page of B3Pdb
The total number entries retrieved from this search are
507
, scroll left/right for detailed information.
B3pdbID
PEPTIDE NAME
PEPTIDE SEQUENCE (1-letter)
PEPTIDE SEQUENCE (3-letter)
N-TERMINAL MODIFICATION
C-TERMINAL MODIFICATION
CHEMICAL MODIFICATION
PEPTIDE LENGTH
PEPTIDE CONFORMATION
PEPTIDE NATURE
SOURCE/ORIGIN OF PEPTIDE
SMILES
CELL LINE
In vitro
CONCENTRATION
In vitro
METHOD
In vitro
RESULT
ANIMAL MODEL
In vivo
CONCENTRATION
In vivo
MODE OF DELIVERY
In vivo
METHOD
In vivo
RESULT
ACTION
TRANSPORT TYPE
SUBCELLULAR LOCALISATION
COMBINATION
PHYSICAL CONDITION
RESPONSE
RESULT
LABEL
PMID
b3pdb_0002
Tf-PFV
PFVYLI
ProPheValTyrLeuIle
NA
NA
NA
6
Linear
Cationic
Chemically synthesized
N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)O
Glioblastoma (U87), brain endothelial (bEnd.3), an
NA
By measuring the flux of sodium fluorescence (Na-F) and TEER
The transport of Tf-PFV liposomes across the endothelial barrier layer into tumor grown in the porou
In vitro brain model
NA
NA
NA
NA
The dual functionalized liposomes showed significantly higher cellular uptake as well as increased t
Transcytosis
NA
Combination with the transferrin protein
Glioblastoma multiforme
NA
NA
NA
30261346
b3pdb_0003
K16ApoE
NA
NA
NA
NA
NA
16
NA
Cationic
Chemically synthesized
NA
hCMEC/D3 monolayers
NA
Laser confocal microscopy
The uptake of AF647-K16ApoE-targeted nanoparticles was substantially greater than the AF647-targeted
WT mice
75 μg/μL
NA
Injected into the femoral vein of 2- year-old APP transgenic (Tg2576) mice
The K16ApoE-targeted nanoparticles showed 8- to 10-fold higher accumulation in various brain regions
It enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain.
Transcytosis
intracellular
It is given in the combination with IgG4.1
Alzheimer’s disease
NA
NA
NA
30300748
b3pdb_0007
D-T7
HRPYIAHC
HisArgProTyrIleAlaHisCys
NA
Cysteine on C-terminal
NA
7
Linear
NA
Chemically synthesized
N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CS)C(=O)O
bEnd.3 and c6 cells
NA
Confocal microscopy
It crosses the BBB.
Mice
PTX-1.7 mg/kg, CD-3.6 mg/kg
Intravenous
NA
NA
D-T7 Peptide Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Ant
NA
NA
Combined with Cediranib and Paclitaxel.
Glioma
Stability/half life
3.31-fold higher than saline
NA
30525386
b3pdb_0008
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.3 micromolar
NA
30824786
b3pdb_0009
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
1.6 ± 0.9micromolar
NA
30824786
b3pdb_0010
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
1.6 ± 0.8 micromolar
NA
30824786
b3pdb_0011
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Alone
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0012
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0013
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0014
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0015
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.9 micromolar
NA
30824786
b3pdb_0016
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.7 micromolar
NA
30824786
b3pdb_0017
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.4 micromolar
NA
30824786
b3pdb_0018
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.3 micromolar
NA
30824786
b3pdb_0019
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.3 micromolar
NA
30824786
b3pdb_0020
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0021
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.3 micromolar
NA
30824786
b3pdb_0022
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0023
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.4 micromolar
NA
30824786
b3pdb_0024
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0025
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0026
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.4 micromolar
NA
30824786
b3pdb_0027
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
50.0 ± 10.2 micromolar
NA
30824786
b3pdb_0028
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 5.1 micromolar
NA
30824786
b3pdb_0029
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0030
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.7 micromolar
NA
30824786
b3pdb_0031
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.7 micromolar
NA
30824786
b3pdb_0032
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 2.2 micromolar
NA
30824786
b3pdb_0033
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0034
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.5 micromolar
NA
30824786
b3pdb_0035
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 5.1 micromolar
NA
30824786
b3pdb_0036
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.9 micromolar
NA
30824786
b3pdb_0037
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.9 micromolar
NA
30824786
b3pdb_0047
C-TN-APNPs
CAQK
CysAlaGlnLys
NA
NA
NA
4
Linear
NA
Chemically synthesized
N[C@@]([H])(CS)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)O
hCMEC/D3 and NHA cells
NA
TEM imaging
Responsive to thrombin cleavage, reduced the cytotoxicity of Tat-NR2B9c, and increased BBB permeabil
C57BL6 mice
NA
Intravenous
Dynamic light scattering
Better circulation time, better targeting ability and penetrating efficiency to the injured brain, a
Treatment reduced the injury size
NA
NA
Combined with Tat-NR2B9c
Traumatic brain injury
NA
NA
NA
31213815
b3pdb_0048
CC-TN-APNPs
CCAQK
CysCysAlaGlnLys
NA
NA
NA
5
Linear
NA
Chemically synthesized
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)O
hCMEC/D3 and NHA cells
NA
TEM imaging
Responsive to thrombin cleavage, reduced the cytotoxicity of Tat-NR2B9c, and increased BBB permeabil
C57BL6 mice
NA
Intravenous
Dynamic light scattering
Better circulation time, better targeting ability and penetrating efficiency to the injured brain, a
Treatment reduced the injury size
NA
NA
Combined with Tat-NR2B9c
Traumatic brain injury
NA
NA
NA
31213815
b3pdb_0049
gH625Cys
HGLASTLTRWAHYNALIRAF
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPhe
Acetylaed at N-terminal
Cys-CONH2 group is attached at C-terminal
NA
21
Linear
NA
Chemically synthesized
N[C@@]([H])(CC1=CN=C-N1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O
BMECs
5 micromolar
Fluorescence microscopy
Liposomes preparations were non-toxic for the endothelial cells and improves the transfer of liposom
Mouse
NA
Intravenous
Fluorescence microscopy
gH625 ameliorates the efficiency of liposomes to deliver. PACAP
gH625-liposomes represent a promising strategy to deliver therapeutic agents to CNS and to provide a
NA
NA
Comined with liposome
NA
NA
NA
NA
31235716
b3pdb_0050
Deltorphan
YAFDVVG
Tyr-(D)Ala-Phe-Asp-Val-Val-Gly-NH2
NA
Amide group is attached
NA
7
Linear
NA
Chemically synthesized
N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)NCC(=O)O
NA
NA
NA
NA
C57BL6 mice
NA
Intravenous
Confocal microscopy
Presence of engineered nano particles within the brain parenchyma with particular focus on hippocamp
Opioid-derived peptides featured by specific helix-like conformation as possible ligands to engineer
NA
CNS parenchyma
Comined
NA
NA
NA
NA
32479916
b3pdb_0051
SLS
SLSHSPQ
SerLeuSerHisSerProGln
NA
NA
NA
7
Cyclic
Neutral
Chemically synthesized
N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CO)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)O
hCMEC/D3 cell monolayers
200000 cells per well
Confocal microscopy
It promoted phage permeation across the hCMEC/D3 cell monolayer.
Mice
NA
Intravenous
Plaque formation assay
Cyclic SLS peptide facilitated phage permeation across the mouse BBB in vivo
BBB-permeable cyclic SLS heptapeptide for brain delivery of macromolecules via macropinocytosis and
Macropinocytosis
Brain parenchyma
Combined with M13 phage
NA
NA
NA
NA
32135226
b3pdb_0052
Phage clone 1.2
VAARTGEIYVPW
ValAlaAlaArgThrGlyGluIleTyrValProTrp
NA
NA
NA
12
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(C(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)O
SH-SY5Y cells
NA
UHPLC-MS/MS
The phage display adverses the BBB with the peptide.
NA
NA
NA
NA
NA
Peptides bound specifically to primary endothelial cells and could traverse the BBB.
Transcytosis
NA
Combined with phage display
NA
Stability/half life
1.5 x 10e-6 cm/s
NA
32079185
b3pdb_0053
Phage clone 1.3
GLHTSATNLYLH
GlyLeuHisThrSerAlaThrAsnLeuTyrLeuHis
NA
NA
NA
12
Linear
Cationic
Chemically synthesized
NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)O
SH-SY5Y cells
NA
UHPLC-MS/MS
The phage display adverses the BBB with the peptide.
NA
NA
NA
NA
NA
Peptides bound specifically to primary endothelial cells and could traverse the BBB.
Transcytosis
NA
Combined with phage display
NA
Stability/half life
3.3 x 10e-7 cm/s
NA
32079185
b3pdb_0054
Tfr1
THRPPMWSPVWP
ThrHisArgProProMetTrpSerProValTrpPro
FAM is conjgated at the N-terminal
NA
NA
12
Linear
NA
Chemically synthesized
N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(CO)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0055
Tfr2
HAIYPRH
HisAlaIleTyrProArgHis
FAM is conjgated at the N-terminal
NA
NA
7
Linear
NA
Chemically synthesized
N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0056
APep2
TFFYGGSRGKRNNFKTEEY
ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr
FAM is conjgated at the N-terminal
NA
NA
19
Linear
NA
Chemically synthesized
N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0057
PPII(R8X)
VRLPPPVXLPPPVRLPPP
ValArgLeuProProProValXaaLeuProProProValArgLeuProProPro
CuAAC conjugated at N-terminus
NA
NA
18
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0058
PPII(R8K)
VRLPPPVKLPPPVRLPPP
ValArgLeuProProProValLysLeuProProProValArgLeuProProPro
Amide conjugated at N-terminus
NA
NA
18
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0059
PPII(L3X)
VRXPPPVRLPPPVRLPPP
ValArgXaaProProProValArgLeuProProProValArgLeuProProPro
CuAAC conjugated at N-terminus
NA
NA
18
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0060
PPII(L15X)
VRLPPPVRLPPPVRXPPP
ValArgLeuProProProValArgLeuProProProValArgXaaProProPro
CuACC conjugated at N-terminus
NA
NA
18
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0061
PPII(L3X;L15X)
VRXPPPVRLPPPVRXPPP
ValArgXaaProProProValArgLeuProProProValArgXaaProProPro
CuAAC conjugated at N-terminus
NA
NA
18
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0062
PPII(L3X;V13X)
VRXPPPVRLPPPXRLPPP
ValArgXaaProProProValArgLeuProProProXaaArgLeuProProPro
CuAAC conjugated at N-terminus
NA
NA
18
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
b3pdb_0063
PPII(L3X;L15K)
VRXPPPVRLPPPVRKPPP
ValArgXaaProProProValArgLeuProProProValArgLysProProPro
Amide and CuAAC conjugated at N-terminus
NA
NA
18
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O
bEnd.3 cells
NA
Immunofluorescence microscopy
It shows the permeability towards the BBB.
NA
NA
NA
NA
NA
These novel peptide conjugates have the capacity to act as promising brain shuttles
Receptor-mediated transcytosis
NA
Combined
NA
NA
NA
NA
32055384
previous
1
2
3
4
5
6
7
8
9
10
11
next
IIITD/CB
Raghava's Group
IMTECH
CellPPDMOD
